EssilorLuxottica Deepens Myopia Insights With New Teen Behavior Study
Essilorluxottica (OTC) (ESLOY) announced an update on their ongoing clinical study.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Essilor International, part of EssilorLuxottica (OTC: ESLOY), is running an interventional study called “Comportement Visuo-postural Des Adolescents Myopes et Non Myopes (CALYPSO).” It looks at how myopic and non-myopic teenagers hold reading material and devices, and whether lens type affects this behavior. The work matters because it may guide future designs for lenses that slow myopia and support safer near-work habits.
The study compares three teen groups: non-myopes, myopes wearing Essilor Stellest lenses, and myopes wearing standard single-vision lenses. Stellest is designed to slow myopia progression, while standard lenses only correct vision. The goal is to see if these options change working distance and daily visual habits, which could support stronger value claims for EssilorLuxottica’s premium lens portfolio.
The trial uses a non-randomized, parallel group design, which means teens are placed in one of three fixed groups rather than shuffled by chance. There is no masking, so both teens and researchers know which lenses are worn. The primary aim is basic research, not direct treatment, but the findings could still influence how eye care professionals choose lenses for young patients.
Participants first receive a standard eye exam using routine ophthalmic devices, with no invasive procedures. At a second visit, they complete everyday tasks like reading or screen use while wearing an eye tracker and motion-capture system. These tools record posture, eye movements, and how close teens hold objects, giving Essilor detailed behavioral data in near-real-life conditions.
The study is currently listed as recruiting, meaning enrollment is underway but results are not yet available. Key setup dates include first submission on February 12, 2026, and a protocol update filed on April 2, 2026. Primary completion and final completion dates are still estimated, signaling the project is in an early to mid-stage and investors should not expect near-term data readouts.
For investors, this update underscores EssilorLuxottica’s push to build evidence around Stellest and its broader myopia-control strategy. Robust behavioral data could strengthen pricing power, support broader reimbursement, and help defend share against rivals like Hoya and CooperCompanies, which are also active in myopia management. While near-term revenue impact is limited, sustained clinical investment tends to support a quality, innovation-driven premium multiple.
The CALYPSO study remains ongoing and recently updated, with full details and any future changes available on the ClinicalTrials portal.
